Medicaid expansion increases CRC screening in Kentucky

A research team evaluating the impact of Medicaid expansion on the rates of colorectal cancer (CRC) screening, incidence, and survival in Kentucky’s low-income population, have found that the number of Medicaid patients who received screening after the expansion was more than triple the number of patients who were screened before the expansion. Additionally, CRC patients relying on Medicaid exhibited improved survival after the expansion compared to before it was implemented. The study.

Scientists demonstrate how high-fat diet drives colorectal cancer growth

A study led by Salk Institute scientists suggests that high-fat diets fuel colorectal cancer growth by upsetting the balance of bile acids in the intestine and triggering a hormonal signal that lets potentially cancerous cells thrive. The study, ‘FXR Regulates Intestinal Cancer Stem Cell Proliferation’, which appeared in Cell could explain why colorectal cancer, which can take decades to develop, is being seen in younger people growing up at a time when higher-fat diets are common.

Study shows annual non-invasive stool test effective for colon cancer screening

A study by Indiana University School of Medicine and the Regenstrief Institute provides the strongest evidence to date to support recommendations that average risk patients can safely opt for an annual, easy-to-use home stool test instead of a screening colonoscopy, according to the outcomes from a study published in the Annals of Internal Medicine.

Looking forward to Dublin 2019: An interview with ACPGBI President, Brendan Moran

In a series of interviews, we will be previewing this year’s ACPGBI annual meeting in Dublin, 1-3 July. We talked to Mr Brendan Moran, President of the ACPGBI, who highlighted some of the key sessions, presentations and speakers, as well as encouraging those with an interest in coloproctology to attend the meeting.

Colorectal cancer cells killed by assassin antibody

A team of researchers at University of Saskatchewan (Uask) led by Dr Humphrey Fonge, an assistant professor in the College of Medicine's medical imaging department, has created an assassin antibody with attached radioactive molecules which cling to colorectal cancer cells and destroy them. The assassin antibody kills the colorectal cancer cell by releasing high energy to the DNA of the cell. Current antibody drug therapies can slow down the spread of colorectal cancer, but do not destroy the existing cancer cells.

Position statement examines role of interventional inflammatory bowel disease in the era of biologic therapy

According to a new statement from a panel of national and international experts in gastroenterology, inflammatory bowel disease (IBD) and other areas, interventional (or therapeutic) IBD endoscopy has an expanding role in the treatment of disease and of adverse events from surgery.

Gene involved in colorectal cancer also causes breast cancer

Rare mutations in the NTHL1 gene, previously associated with colorectal cancer, also cause breast cancer and other types of cancer. Researchers from Radboud University Medical Center, Leiden University Medical Center and the Princess Máxima Center in the Netherlands report this new multi-tumor syndrome, in collaboration with international colleagues, in Cancer Cell (‘Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype’).

Check-Cap gains IRB approval to initiate US pilot study of C-scan for the detection of precancerous colorectal polyps

Check-Cap has received Institutional Review Board (IRB) approval from New York University School of Medicine to initiate a U.S. pilot study of the C-Scan system. According to the company, C-Scan is the first and only preparation-free ingestible scanning capsule for the prevention of colorectal cancer (CRC) through the detection of precancerous polyps.